Association of plasminogen activator inhibitor-1 4G/5G gene polymorphism with variations in the LDL particle size in healthy Japanese men

Clinica Chimica Acta

Volumn 347, Issue 1-2, 2004, Pages 209-216

  Kitamura, Yoko ^a   Okumura, Kenji ^a   Imamura, Akiko ^a   Mizuno, Tomofumi ^a   Tsuzuki, Michitaka ^a   Numaguchi, Yasushi ^a   Matsui, Hideo ^a   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Genotype; Japanese men; LDL particle size; Plasminogen activator inhibitor 1

Indexed keywords

INSULIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYACRYLAMIDE GEL; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIET RESTRICTION; DNA POLYMORPHISM; ETHNIC GROUP; GENOTYPE; HEALTH STATUS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; MULTIPLE REGRESSION; MULTIVARIATE ANALYSIS OF COVARIANCE; NORMAL HUMAN; PARTICLE SIZE; PLASMA; PRIORITY JOURNAL;

ADULT; AGED; DNA; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE FREQUENCY; GENOTYPE; HUMANS; JAPAN; LEUKOCYTES; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VARIATION (GENETICS);

EID: 4143129941     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.04.014     Document Type: Article

References (48)

1. Krauss R.M., Burke D.J. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J. Lipid Res. 23:1982;97-104
2. Shen M.M.S., Krauss R.M., Lindgren F.T., Forte T.M. Heterogeneity of serum low density lipoproteins in normal human subjects. J. Lipid Res. 22:1981;236-244
3. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 260:1988;1917-1921
4. Campos H., Genest J.J. Jr., Blijlevens E., et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler. Thromb. 12:1992;187-195
5. Lamarche B., Tchernof A., Moorjani S., et al. Small, dense, low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from Québec Cardiovascular Study. Circulation. 95:1997;69-75
6. Crouse J.R., Parks J.S., Schey H.M., Kahl F.R. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J. Lipid Res. 26:1985;566-574
7. Aznar J., Estelles A., Tormo G., et al. Plasminogen activator inhibitor activity and other fibrionolytic variables in patients with coronary artery disease. Br. Heart J. 59:1998;535-541
8. Almér L., Öhlin H. Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction. Thromb. Res. 47:1987;335-339
9. Hamsten A., Wiman B., de Faire U., Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 313:1985;1557-1563
10. Hamsten A., Blombäck M., Wiman B., et al. Haemostatic function in myocardial infarction. Br. Heart J. 55:1986;58-66
11. Johnson O., Mellbring G., Nilsson T. Detective fibrinolysis in survivors of myocardial infarction. Int. J. Cardiol. 6:1984;380-382
12. Paramo J.A., Colucci M., Collen D., van de Werf Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br. Med. J. 291:1985;573-574
13. Hamsten A., de Faire U., Walldius G., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 2:1987;3-8
14. Kruithof E.K.O., Tran-Thang C., Ransijn A., Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood. 64:1984;907-913
15. Lindahl T.L., Ohlsson P.I., Wiman B. The mechanism of the reaction between human plasminogen activator inhibitor 1 and tissue plasminogen activator. Biochem. J. 265:1990;109-113
16. Dawson S., Hamsten A., Wiman B., Henney A., Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler. Thromb. 11:1991;183-190
17. Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J. Biol. Chem. 268:1993;10739-10745
18. Henry M., Chomiki N., Scarabin P.Y., et al. Five frequent polymorphism of the PAI-1 gene: lack of association between genotypes, PAI-1 activity, and triglyceride levels in a healthy population. Arterioscler. Thromb. Vasc. Biol. 17:1997;851-858
19. Eriksson P., Kallin B., van't Hooft F.M., Båvenholm P., Hamsten A. Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. U.S.A. 92:1995;1851-1855
20. Ye S., Green F.R., Scarabin P.Y., et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb. Haemost. 74:1995;837-841
21. Ossei-Gerning N., Mansfield M.W., Stickland M.H., Wilson I.J., Grant P.J. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler. Thromb. Vasc. Biol. 17:1997;33-37
22. Chen C.H., Eng H.L., Chang C.J., et al. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J. Lab. Clin. Med. 142:2003;100-105
23. Väisänen S., Baumstark M.W., Penttilä I., et al. Small, dense LDL particle concentration correlates with plasminogen activator inhibitor type-1 (PAI-1) activity. Thromb. Haemost. 78:1997;1495-1499
24. Okumura K., Matsui H., Kawasaki K., et al. Low density lipoprotein particle size is associated with glycosylated hemoglobin levels regardless of plasma lipid levels. Intern. Med. 37:1998;273-279
25. Krauss R.M., Burke D.J. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J. Lipid Res. 23:1982;97-104
26. Margaglione M., Grandone E., Cappucci G., et al. An alternative method for PAI-1 promoter polymorphim (4G/5G) typing. Thromb. Haemost. 77:1997;605-606
27. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502
28. Grundy S.M. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 95:1997;1-4. [Editorial]
29. Lupu F., Bergonzelli G.E., Heim D.A., et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler. Thromb. 13:1993;1090-1100
30. McNamara J.R., Campos H., Ordovas J.M., Peterson J., Wilson P.W.F., Schaefer E.J. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arteriosclerosis. 7:1987;483-490
31. Swinkels D.W., Demacker P.N.M., Hendriks J.C.M., van't Laar A. Low density lipoprotein subfractions and relationship to other risk factors for coronary artery disease in healthy individuals. Arteriosclerosis. 9:1989;604-613
32. Okumura K., Matsui H., Kawakami K., et al. Relationship between the apolipoprotein E and angiotensin-converting enzyme genotypes and LDL particle size in Japanese subjects. Clin. Chim. Acta. 285:1999;91-103
33. Okumura K., Matsui H., Kamiya H., Saburi Y., Hayashi K., Hayakawa T. Differential effect of two common polymorphisms in the cholesterol ester transfer protein gene on low-density lipoprotein particle size. Atherosclerosis. 161:2002;425-431
34. Roest M., van der Schouw Y.T., Banga J.D., et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation. 101:2000;67-70
35. Hoekstra T., Geleijnse J.M., Kluft C., Giltay E.J., Kok F.J., Schouten E.G. 4G/4G genotype of PAI-1 gene is associated with reduced risk of Stroke in elderly. Stroke. 34:2003;2822-2829
36. Catto A.J., Carter A.M., Stickland M., Bamford J.M., Davies J.A., Grant P.J. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb. Haemost. 77:1997;730-734
37. 3 binding to vitronectin. Nature. 383:1996;441-443
38. Carmeliet P., Moons L., Lijnen R., et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation. 96:1997;3180-3191
39. de Waard V., Arkenbout E.K., Carmeliet P., Lindner V., Pannekoek H. Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arterioscler. Thromb. Vasc. Biol. 22:2002;1978-1983
40. Matsubara Y., Murata M., Issiki I., et al. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels. Int. J. Hematol. 69:1999;43-47
41. Sironi L., Mussoni L., Prati L., et al. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler. Thromb. Vasc. Biol. 16:1996;89-96
42. Fattal P.G., Schneider D.J., Sobel B.E., Billadello J.J. Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J. Biol. Chem. 267:1992;12412-12415
43. Eriksson P., Nilsson L., Karpe F., Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridmia. Arterioscler. Thromb. Vasc. Biol. 18:1998;20-26
44. Schäfer K., Fujisawa K., Konstantinides S., Loskutoff D.J. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J. 15:2001;1840-1842
45. Hoffstedt J., Andersson I.L., Persson L., Isaksson B., Arner P. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia. 45:2002;584-587
46. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin in obesity. Biochem. Biophys. Res. Commun. 257:1999;79-83
47. Kazumi T., Kawaguchi A., Sakai K., Hirano T., Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher increased heart rate than those with optimal blood pressure. Diabetes Care. 25:2002;971-976
48. Friedlander Y., Kidron M., Caslake M., Lamb T., McConnell M., Bar-On H. Low density lipoprotein particle size and risk factors of insulin resistance syndrome. Atherosclerosis. 148:2000;141-149